Login to Your Account



Bad News For J&J's EPO Drug, But Amgen Still Riding High

By Randall Osborne


Monday, July 22, 2002
These are the days of Amgen Inc. All eyes were on the biotechnology giant last week, when its $10.3 billion buyout of Immunex Corp. was completed although for less money than originally expected, it was still the largest deal in the industry thus far and as the deadline came for an FDA decision on Aranesp (darbepoetin alpha) in oncology. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription